Polyamine Dysregulation in Metabolic Dysfunction-associated Steatotic Liver Disease: a Systematic Review of Human Observational Evidence
8 affiliations
- 1Department of Endocrinology and Nutrition, Regional University Hospital of Málaga, Málaga, Spain
- 2Biomedical Research Institute of Málaga and Platform in Nanomedicine (IBIMA-BIONAND), Málaga, Spain
- 3Department of Surgical Specialties, Biochemistry and Immunology, Faculty of Medicine, University of Málaga, Málaga, Spain
- 4Medical Oncology Clinical Management Unit, Virgen de La Victoria University Hospital, Málaga, Spain
- 5Department of Medicine and Dermatology, Faculty of Medicine, University of Málaga, Málaga, Spain
- 6Department of Gastroenterology, Regional University Hospital of Málaga, Málaga, Spain
- 7Obesity, Diabetes and Metabolism Research Group, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain
- 8Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas, Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
Abstract
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and is closely associated with obesity, insulin resistance, and increased cardiovascular risk. Polyamines have emerged as potential regulators of metabolic and inflammatory pathways implicated in MASLD. We aimed to systematically evaluate the association between polyamines and MASLD severity and related hepatic and metabolic outcomes in human observational studies.
Approach and Results: A systematic review was conducted in accordance with PRISMA 2020. PubMed, Embase, Web of Science and Scopus were searched from inception to April 2026 (PROSPERO registration CRD420261540945). Observational studies assessing polyamine levels or polyamine-related pathways in relation to MASLD and related hepatic or metabolic outcomes were included. Study selection, data extraction, and risk of bias assessment (Newcastle–Ottawa Scale, NOS) were performed independently. A qualitative synthesis was undertaken. Nine studies were included, comprising more than 1,400 participants across clinical cohorts, together with transcriptomic analyses based on publicly available datasets; NOS scores ranged from 6 to 9. Increased hepatic putrescine, together with upregulation of ornithine decarboxylase, was associated with greater histological disease severity and hepatocellular injury in one study. In contrast, lower spermidine levels in circulating and fecal samples were associated with greater disease severity in some studies. Alterations in polyamine-related molecular pathways, including the eukaryotic initiation factor 5A hypusination pathway, and changes in microbially derived polyamines were also associated with disease severity. Findings varied across studies, with differences in biological matrices, analytical approaches, and disease assessment methods potentially contributing to the observed heterogeneity.
Conclusions: Distinct alterations in polyamine profiles, particularly increased putrescine and reduced spermidine in specific biological matrices, were associated with MASLD-related disease severity in some observational studies. However, none of the included studies established diagnostic performance using measures such as area under the receiver operating characteristic curve (AUC), sensitivity, specificity, predefined cut-offs, or external validation. Therefore, polyamines should currently be considered promising candidate molecular biomarkers requiring prospective validation rather than established biomarkers of MASLD severity. The available evidence remains observational and heterogeneous, precluding definitive causal inferences and limiting conclusions regarding clinical utility. Prospective, longitudinal, and multicenter studies using standardized analytical methods, predefined thresholds, and appropriate internal and external validation are required to determine whether polyamine measurements provide incremental value beyond established non-invasive tools.
Related
- Hyperglycemia induces endothelial mitochondrial dysfunction and myeloperoxidase dysregulation in PCOS iPSCs
- Co-Enrichment of Desulfovibrio and Erysipelotrichaceae and Dysregulation of Multiple Amino Acid Pathways in HFpEF: Insights into TXG-Associated Metabolic Changes
- Convergent Early Dysregulation of Sarcopenia-Associated Genes in Skeletal Muscle During Aging and SOD1G93A ALS Models
- Tau is an m6A-associated RNA binding protein that causes RNA dysregulation in disease
- Dysregulation of mechanosensing signaling in monocytes of patients with systemic sclerosis is associated with skin inflammation
BibTeX
@article{gonzalezgonzalez2026polyamine,
title = {{Polyamine Dysregulation in Metabolic Dysfunction-associated Steatotic Liver Disease: a Systematic Review of Human Observational Evidence}},
author = {Alicia González-González and Lucía Aránega-Martín and Kamar Ouahbi-Chadli and Miguel Jiménez-Pérez and Bruno Ramos-Molina and Gabriel Olveira and José Carlos Fernández-García},
journal = {Current Obesity Reports},
year = {2026},
month = nov,
doi = {10.1007/s13679-026-00774-9},
url = {https://doi.org/10.1007/s13679-026-00774-9},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Polyamine Dysregulation in Metabolic Dysfunction-associated Steatotic Liver Disease: a Systematic Review of Human Observational Evidence
AU - Alicia González-González
AU - Lucía Aránega-Martín
AU - Kamar Ouahbi-Chadli
AU - Miguel Jiménez-Pérez
AU - Bruno Ramos-Molina
AU - Gabriel Olveira
AU - José Carlos Fernández-García
PY - 2026
DA - 2026/11/11
JO - Current Obesity Reports
DO - 10.1007/s13679-026-00774-9
UR - https://doi.org/10.1007/s13679-026-00774-9
AB - Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and is closely associated with obesity, insulin resistance, and increased cardiovascular risk. Polyamines have emerged as potential regulators of metabolic and inflammatory pathways implicated in MASLD. We aimed to systematically evaluate the association between polyamines and MASLD severity and related hepatic and metabolic outcomes in human observational studies. Approach and Results: A systematic review was conducted in accordance with PRISMA 2020. PubMed, Embase, Web of Science and Scopus were searched from inception to April 2026 (PROSPERO registration CRD420261540945). Observational studies assessing polyamine levels or polyamine-related pathways in relation to MASLD and related hepatic or metabolic outcomes were included. Study selection, data extraction, and risk of bias assessment (Newcastle–Ottawa Scale, NOS) were performed independently. A qualitative synthesis was undertaken. Nine studies were included, comprising more than 1,400 participants across clinical cohorts, together with transcriptomic analyses based on publicly available datasets; NOS scores ranged from 6 to 9. Increased hepatic putrescine, together with upregulation of ornithine decarboxylase, was associated with greater histological disease severity and hepatocellular injury in one study. In contrast, lower spermidine levels in circulating and fecal samples were associated with greater disease severity in some studies. Alterations in polyamine-related molecular pathways, including the eukaryotic initiation factor 5A hypusination pathway, and changes in microbially derived polyamines were also associated with disease severity. Findings varied across studies, with differences in biological matrices, analytical approaches, and disease assessment methods potentially contributing to the observed heterogeneity. Conclusions: Distinct alterations in polyamine profiles, particularly increased putrescine and reduced spermidine in specific biological matrices, were associated with MASLD-related disease severity in some observational studies. However, none of the included studies established diagnostic performance using measures such as area under the receiver operating characteristic curve (AUC), sensitivity, specificity, predefined cut-offs, or external validation. Therefore, polyamines should currently be considered promising candidate molecular biomarkers requiring prospective validation rather than established biomarkers of MASLD severity. The available evidence remains observational and heterogeneous, precluding definitive causal inferences and limiting conclusions regarding clinical utility. Prospective, longitudinal, and multicenter studies using standardized analytical methods, predefined thresholds, and appropriate internal and external validation are required to determine whether polyamine measurements provide incremental value beyond established non-invasive tools.
SN - 2162-4968
ER -